

INTERIM REPORT – Extract from the official Swedish report

1 January – 30 September 2017
(NGM: LIFE B)



Financial information

Group

- Net sales for the period January – September 2017 totals 4 668 (5 623) kSEK
- Profit after taxes totals – 15 034 (-13 847) kSEK.
- Profit per share was – 0,01 (-0,01) kr.

Parent company

- Net sales for the period January – September 2017 totals 4 651 (5 623) kSEK.
- Profit after taxes totals – 12 897 (-11 978) kSEK.
- Profit per share was – 0,01 (-0,01) SEK.



LifeAssays® AB's business idea is to develop, manufacture and sell diagnostic systems based on the company's own and patented technology MagnetoImmunoAssay (MLA). The company delivers safe and robust systems for quick and reliable analysis in veterinary medicine. The company's patented products consist of instruments and disposable reagent which is harmless to patients, staff and the environment. Alternative markets for the company's products are in human medicine as well as food and pharmaceutical industries.

CEO comments

Third quarter 2017

- Net sales for the Group as well during the quarter was 1 277 kSEK which is a decrease of 22% over the third quarter 2016
- Sales in Q3 was adversely affected by no sales to Korea and a decline in sales in the Nordic region during the summer. Sales in the Nordic region is in September again at the expected level.
- Our new SAA Cat Inflammation Marker, launched this spring, has already sold the equivalent of 90% of last year's sales of our cat test in the Nordic countries, and in China all customers have now been transferred to this product. The product was registered in Korea during September.
- The development of the quantitative disposable test is proceeding according to plan and an integrated test treatment unit has been developed in parallel.
- The targeted share issue to our Chinese partner St. Grand, decided in March this year, was unfortunately canceled during the third quarter, as the payment for the subscribed shares could not be transferred out of China. The Board has, in order to secure continued financing of the ongoing investments and further to avoid the risk that the company's equity capital falls below half of the registered share capital during the autumn 2017, called an Extraordinary General Meeting to decide on a new share issue.

20th of October 2017

Anders Ingvarsson, MSc

VD för LifeAssays AB

anders.ingvarsson@lifeassays.com

Share information & owner structure

The share price (last transaction) for the quarter was 0,027 (0,038) SEK, which gives a market cap of 57,2 (62,9) mSEK. The nominal value is 0,02 kr.

The average number of shares for the period was 1 840 644 580 shares.

Largest owners 30th of September 2017	No of shares	Votes/equity
Tibia Konsult AB	185 694 934	8,77%
Biothom Oy	144 811 908	6,84%
Avanza Pension	102 945 262	4,86%
Matz Eklund	67 150 440	3,17%
Peter Schlein-Andersen	61 050 000	2,88%
Nordnet Pensionsförsäkring AB	54 501 384	2,57%
Bo Göran Åkerlund	47 200 000	2,23%
Christian Borgvall	30 000 000	1,42%
AN Holding	24 000 000	1,13%
Ingemar Värendh	22 112 209	1,04%
Others	1 378 383 243	65,08%
Total	2 117 849 380	100,00%

Outstanding warrants

There are currently no outstanding warrants.

Significant events after the end of the quarter

No significant events has occurred after the end of the quarter.

Financial calendar

Q4 report 2017

February 2018

This report has not been audited by the company auditors.

Contact information:

LifeAssays® AB, Sölvegatan 43A, 223 70 LUND, tel +46 46-286 5400, fax +46 46-286 5419

Web: www.lifeassays.com, epost: info@lifeassays.com

For further information contact CEO of LifeAssays AB, Anders Ingvarsson, telephone +46 46-286 54 00 or email: info@lifeassays.com

Condensed statement of comprehensive income - Gruop

TSEK	2017 Jul-Sept	2016 Jul-Sept	2017 43008	2016 43008	2016 Jan-Dec
Net sales					
Net sales	1 277	1 645	4 668	5 623	7 456
Other income	174	26	205	80	111
Total net sales	1 451	1 671	4 873	5 703	7 567
Operating expenses					
Raw materials and consumables	-482	-680	-1 728	-2 481	-3 231
Other external expenses	-2 472	-2 055	-7 190	-6 836	-9 131
Personnel expenses	-2 809	-2 727	-9 334	-8 922	-12 367
Depreciation and writedowns of intangible and tangible assets	-444	-390	-1 264	-1 160	-1 586
Other operating income/cost					
Total operating expenses	-6 207	-5 852	-19 516	-19 399	-26 315
Operating profit/loss	-4 756	-4 181	-14 643	-13 696	-18 748
Profit /loss from financial activities					
Interest income	14	57	9	91	54
Interest expenses	-206	-34	-364	-259	-351
Profit before taxes	-4 948	-4 158	-14 998	-13 864	-19 045
Taxes	-22	-8	-36	17	18
Profit/loss for the period	-4 970	-4 166	-15 034	-13 847	-19 027
TSEK	2017 Jul-Sept	2016 Jul-Sept	2017 43008	2016 43008	2016 Jan-Dec
Profit/loss for the period	-4 970	-4 166	-15 034	-13 847	-19 027
Items that may be reclassified to the income statement:					
Translation differences	0	21	183	26	-14
Total comprehensive income for the period	-4 970	-4 145	-14 851	-13 821	-19 041
Key ratios:					
Earnings per share before and after dilution	-0,002	0,00	-0,01	-0,01	-0,02
Average number of shares	2 095 737 171	1 631 269 069	1 840 644 580	1 045 901 062	1 199 765 939
Number of shares at the end of the period	2 095 737 171	1 656 343 234	2 095 737 171	1 656 343 234	1 656 343 234

Condensed consolidated balance sheet - Group

TSEK	2017-09-30	2016-09-30	2016-12-31
Assets			
Fixed assets			
Intangible fixed assets	23 624	18 752	19 266
Tangible assets	431	478	459
Total fixed assets	24 055	19 230	19 725
Current assets			
Inventories	2 455	1 986	1 830
Other current assets	3 339	3 150	2 889
Liquid assets, including current investments	1 912	13 331	8 472
Total current assets	7 706	18 467	13 191
Total assets	31 761	37 697	32 916
Liabilities and shareholders equity			
Share capital	41 915	33 127	33 127
Other capital contributed	145 430	127 895	141 262
Reserves	268	85	85
Profit/Loss brought forward	-156 873	-124 479	-137 846
Total comprehensive income for the period	-14 851	-13 847	-19 027
Total equity	15 889	22 781	17 601
Long term liabilities			
	10 148	9 774	9 763
Deferred tax liabilities	2 076	2 036	2 022
Total long-term liabilities	12 224	11 810	11 785
Current liabilities			
Other current liabilities	3 648	3 106	3 530
Total current liabilities	3 648	3 106	3 530
Total liabilities and shareholders equity	31 761	37 697	32 916

Consolidated Cash flow statement - Group

TSEK	2017 Jul-Sept	2016 Jul-Sept	2017 43008	2016 43008	2016 Jan-Dec
Operating activities					
Operating profit/loss	-4 756	-4 181	-14 643	-13 696	-18 748
Interest received	14	57	9	99	54
Interest paid	-206	-34	-364	-259	-351
Other items not included in cash flow	447	270	1 068	1 240	1 759
Cash flow from operating activities before changes in working capital	-4 501	-3 888	-13 930	-12 616	-17 286
Change in operating receivables	-506	-302	-625	138	294
Change in inventory	-65	359	-450	-852	-592
Change in operating liabilities	322	-444	537	56	493
Cash flow from operating activities	-4 750	-4 275	-14 468	-13 274	-17 091
Investment activities					
Intangible assets	-2 525	-21	-5 542	-1 673	-2 702
Fixed assets	-41	1	-55	-314	-322
Total cash flow from investment activities	-2 566	-20	-5 597	-1 987	-3 024
Financing activities					
New share issue	0	4 049	12 956	22 344	22 344
Change in financial receivables	109	179	549	563	570
Cash flow from financing activities	109	4 228	13 505	22 344	22 914
Cash flow for the period	-7 207	-67	-6 560	7 083	2 799
Liquid assets at the beginning of the period	9 121	13 377	8 472	5 659	5 659
Exchange rate difference liquid assets	-2	21	0	26	14
Cash flow for the period	-7 207	-67	-6 560	7 646	2 799
Liquid assets at the end of the period	1 912	13 331	1 912	13 331	8 472

Key ratios - Group	2 017 Jul-Sept	2016 Jul-Sept	2 017 43 008	2016 43008	2016 Jan-Dec
Equity/asset ratio (%)	50%	60%	50%	60%	53%
Return on equity	neg	neg	neg	neg	neg
Profit/loss after finance net (TSEK)	-4 948	-4 158	-14 998	-13 864	-19 045
Profit/loss per share (sek/share)	-0,002	0,00	-0,01	-0,01	-0,02
Cash flow (TSEK)	-7 207	-67	-6 560	7 646	2 799

Consolidated changes in shareholders equity

TSEK	Share capital	Other capital contributed	Reserves	Profit/loss brought forward	Profit/loss for the year	Shareholders equity
Opening balance	33 127	141 262	85	-137 846	-19 027	17 601
Disposition of previous years' result				-19 027	19 027	0
Ongoing share issue						0
Reduction of share capital						0
Share issue	8 788	4 168				12 956
Redemption of warrants						0
Translation difference group companies			183			183
Profit/loss for the year					-14 851	-14 851
Closing balance	41 915	145 430	268	-156 873	-14 851	15 889

Segment information

Split of Net sales per product group	2017	2016	2017	2016	2016
	Jul-Sept	Jul-Sept	Jan-Sept	Jan-Sept	Jan-Dec
Tester	1208	1451	4072	4 865	6342
Instrument	38	82	426	413	868
Övrigt	31	112	170	345	246
Total	1 277	1 645	4 668	5 623	7 456

Net sales per region (Split based on where the customers are established)	2017	2016	2017	2016	2016
	Jul-Sept	Jul-Sept	Jan-Sept	Jan-Sept	Jan-Dec
Nordic	1 050	1 230	3 413	3 730	4 879
Europé	16	100	93	275	453
North America	5	6	5	19	19
Asia	206	309	1 157	1 599	2 105
Total	1 277	1 645	4 668	5 623	7 456